Jeffrey A. Bailey

Board Chairperson (since 2022), HQH, HQL, THQ and THW Trustee (since 2020); CEO, IlluminOss Inc. (2018 to 2020); Vice President, Janssen Pharmaceutica (Johnson & Johnson) (1984-2006); Board Chairperson, Aileron Therapeutics Inc. (since 2018); Director, Madison Vaccines, Inc. (since 2018); Director and CEO, BioDelivery Systems, Inc. (2020 to 2022).

Kathy L. Goetz

Trustee, HQH, HQL, THQ and THW (since 2021); Consultant (Since 2020); Novartis Pharmaceuticals: Vice President and Head of Sales (2017-2019), Executive Director of Strategic Account Management (2015-2016), Regional Sales Director - Neuroscience Business Unit (2012-2015), Marketing Brand Director - Reclast (2011), Ad Interim General Manager (2010), Managing Sales Director (2008-2010) and Integrated Markets, Strategic Planning (2007-2008).

Rakesh K. Jain, PhD

Trustee, HQH, HQL (since 2007), THQ (since 2014) and THW (since 2015); Director, Steele Lab of Tumor Biology at Massachusetts General Hospital (since 1991); A.W. Cook Professor of Tumor Biology (Radiation Oncology) at Harvard Medical School (since 1991); Ad hoc Consultant/Scientific Advisory Board Member for pharmaceutical/biotech companies (various times since 2002); Ad hoc Consultant, Gershon Lehman Group (since 2004); Director, Co-Founder, XTuit Pharmaceuticals, Inc. (2012-2018).

Thomas M. Kent, CPA

Trustee, HQH, HQL, THQ and THW (since 2017); Partner, PricewaterhouseCoopers LLP (1989-2013); Director, Principal Global Investors Trust Co. (since 2014); Director, Thayer Academy (2009-2018); Director, New England Canada Business Council (since 2017).

Daniel R. Omstead, Ph*

Trustee, HQH, HQL (since 2003), THQ (since 2014) and THW (since 2015); President, HQH, HQL (since 2001), THQ (since 2014) and THW (since 2015); Chief Executive Officer and Managing Member, Tekla Capital Management LLC (since 2002).

W. Mark Watson, CPA

Trustee, (since 2022); Partner, Deloitte & Touche LLP (1973-2013); Director, BioDelivery Sciences International, Inc. (2017-2022); Director, Inhibitor Therapeutics, Inc. (since 2014); Director, Global Health MCS, (since 2014); Director, Sykes Enterprises, Inc. (2018-2021); Director, The Moffitt Cancer Center (since 2009).

* Trustee considered to be an “interested person” within the meaning of the Investment Company Act of 1940, as amended, through a position or affiliation with Tekla Capital Management LLC.